This comprehensive report provides a detailed analysis of the global combination and multivalent vaccine market, forecasting its trajectory through 2032. The study evaluates key growth drivers and trends across various product types and applications, including hospital and CDC sectors. By examining regional dynamics in the Americas, APAC, Europe, and MEA, the report identifies emerging opportunities and competitive landscapes. Furthermore, it profiles major industry players like Merck, Pfizer, and Sanofi to assess market share and strategic positioning.

Executive Overview

Global Market Outlook

The global Combination Vaccine and Multivalent Vaccine market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate throughout the forecast period.

Regional Market Projections

• United States: The market for Combination Vaccine and Multivalent Vaccine in the United States is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• China: The market for Combination Vaccine and Multivalent Vaccine in China is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• Europe: The market for Combination Vaccine and Multivalent Vaccine in Europe is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.

About the Report

LPI (LP Information)' newest research report, the “Combination Vaccine and Multivalent Vaccine Industry Forecast,” reviews total world Combination Vaccine and Multivalent Vaccine sales in 2025 based on past sales data. The report provides a comprehensive analysis by region and market sector of projected Combination Vaccine and Multivalent Vaccine sales for the period from 2026 through 2032. By breaking down sales by region, market sector, and sub-sector, this report provides a detailed analysis in US$ millions of the global Combination Vaccine and Multivalent Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Combination Vaccine and Multivalent Vaccine landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Furthermore, the report analyzes the strategies of leading global companies with a focus on Combination Vaccine and Multivalent Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints to better understand these firms’ unique positions in an accelerating global market.

The report evaluates key market trends, drivers, and affecting factors shaping the global outlook for Combination Vaccine and Multivalent Vaccine. It breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. Utilizing a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory of the global Combination Vaccine and Multivalent Vaccine industry. It presents a comprehensive overview, market shares, and growth opportunities categorized by product type, application, key players, and key regions and countries.

Market Segmentation

By Type

• Combination Vaccine
• Multivalent Vaccine

By Application

• Hospital
• Centers for Disease Control and Prevention
• Others

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Players and Market Share

Global key Combination Vaccine and Multivalent Vaccine players include Merck & Co., Pfizer, Sanofi Pasteur, GlaxoSmithKline, and BioNTech, among others. In terms of revenue, the two largest companies in the global market occupied a significant share in 2025.

Profiled Companies

The following companies have been profiled based on inputs gathered from primary experts and analysis of company coverage, product portfolios, and market penetration:

• Merck & Co.
• Pfizer
• Sanofi Pasteur
• GlaxoSmithKline
• BioNTech
• Moderna
• Dynavax
• Novavax
• Sino Biopharm
• Kangtai Bio
• Zhifei Biological
• Walvax
• Minhai Biological
• Sinovac
• Wantai Biological
• Wanbangde Pharmaceutical
• AIM Bio
• Antejin Biotechnology
• Lanzhou Institute of Biological Products
• Wuhan Institute of Biological Products
• Beijing Institute of Biological Products
• Chengdu Institute of Biological Products

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Combination Vaccine and Multivalent Vaccine Market Size (2021-2032)

    • 2.1.2 Combination Vaccine and Multivalent Vaccine Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Combination Vaccine and Multivalent Vaccine by Country/Region (2021, 2025 & 2032)

  • 2.2 Combination Vaccine and Multivalent Vaccine Segment by Type

    • 2.2.1 Combination Vaccine

    • 2.2.2 Multivalent Vaccine

    • 2.2.3 Combination Vaccine and Multivalent Vaccine Market Size by Type

      • 2.2.3.1 Combination Vaccine and Multivalent Vaccine Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.3.2 Global Combination Vaccine and Multivalent Vaccine Market Size Market Share by Type (2021-2026)

  • 2.3 Combination Vaccine and Multivalent Vaccine Segment by Application

    • 2.3.1 Hospital

    • 2.3.2 Centers for Disease Control and Prevention

    • 2.3.3 Others

    • 2.3.4 Combination Vaccine and Multivalent Vaccine Market Size by Application

      • 2.3.4.1 Combination Vaccine and Multivalent Vaccine Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.4.2 Global Combination Vaccine and Multivalent Vaccine Market Size Market Share by Application (2021-2026)

• 3 Combination Vaccine and Multivalent Vaccine Market Size by Player

  • 3.1 Combination Vaccine and Multivalent Vaccine Market Size Market Share by Player

    • 3.1.1 Global Combination Vaccine and Multivalent Vaccine Revenue by Player (2021-2026)

    • 3.1.2 Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Player (2021-2026)

  • 3.2 Global Combination Vaccine and Multivalent Vaccine Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Combination Vaccine and Multivalent Vaccine by Region

  • 4.1 Combination Vaccine and Multivalent Vaccine Market Size by Region (2021-2026)

  • 4.2 Global Combination Vaccine and Multivalent Vaccine Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Combination Vaccine and Multivalent Vaccine Market Size Growth (2021-2026)

  • 4.4 APAC Combination Vaccine and Multivalent Vaccine Market Size Growth (2021-2026)

  • 4.5 Europe Combination Vaccine and Multivalent Vaccine Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)

  • 5.2 Americas Combination Vaccine and Multivalent Vaccine Market Size by Type (2021-2026)

  • 5.3 Americas Combination Vaccine and Multivalent Vaccine Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Combination Vaccine and Multivalent Vaccine Market Size by Region (2021-2026)

  • 6.2 APAC Combination Vaccine and Multivalent Vaccine Market Size by Type (2021-2026)

  • 6.3 APAC Combination Vaccine and Multivalent Vaccine Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)

  • 7.2 Europe Combination Vaccine and Multivalent Vaccine Market Size by Type (2021-2026)

  • 7.3 Europe Combination Vaccine and Multivalent Vaccine Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Combination Vaccine and Multivalent Vaccine by Region (2021-2026)

  • 8.2 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Combination Vaccine and Multivalent Vaccine Market Forecast

  • 10.1 Global Combination Vaccine and Multivalent Vaccine Forecast by Region (2027-2032)

    • 10.1.1 Global Combination Vaccine and Multivalent Vaccine Forecast by Region (2027-2032)

    • 10.1.2 Americas Combination Vaccine and Multivalent Vaccine Forecast

    • 10.1.3 APAC Combination Vaccine and Multivalent Vaccine Forecast

    • 10.1.4 Europe Combination Vaccine and Multivalent Vaccine Forecast

    • 10.1.5 Middle East & Africa Combination Vaccine and Multivalent Vaccine Forecast

  • 10.2 Americas Combination Vaccine and Multivalent Vaccine Forecast by Country (2027-2032)

    • 10.2.1 United States Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.2.2 Canada Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.2.3 Mexico Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.2.4 Brazil Market Combination Vaccine and Multivalent Vaccine Forecast

  • 10.3 APAC Combination Vaccine and Multivalent Vaccine Forecast by Region (2027-2032)

    • 10.3.1 China Combination Vaccine and Multivalent Vaccine Market Forecast

    • 10.3.2 Japan Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.3.3 Korea Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.3.4 Southeast Asia Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.3.5 India Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.3.6 Australia Market Combination Vaccine and Multivalent Vaccine Forecast

  • 10.4 Europe Combination Vaccine and Multivalent Vaccine Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.4.2 France Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.4.3 UK Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.4.4 Italy Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.4.5 Russia Market Combination Vaccine and Multivalent Vaccine Forecast

  • 10.5 Middle East & Africa Combination Vaccine and Multivalent Vaccine Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.5.2 South Africa Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.5.3 Israel Market Combination Vaccine and Multivalent Vaccine Forecast

    • 10.5.4 Turkey Market Combination Vaccine and Multivalent Vaccine Forecast

  • 10.6 Global Combination Vaccine and Multivalent Vaccine Forecast by Type (2027-2032)

  • 10.7 Global Combination Vaccine and Multivalent Vaccine Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Combination Vaccine and Multivalent Vaccine Forecast

• 11 Key Players Analysis

  • 11.1 Merck & Co.

    • 11.1.1 Merck & Co. Company Information

    • 11.1.2 Merck & Co. Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.1.3 Merck & Co. Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Merck & Co. Main Business Overview

    • 11.1.5 Merck & Co. Latest Developments

  • 11.2 Pfizer

    • 11.2.1 Pfizer Company Information

    • 11.2.2 Pfizer Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.2.3 Pfizer Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Pfizer Main Business Overview

    • 11.2.5 Pfizer Latest Developments

  • 11.3 Sanofi Pasteur

    • 11.3.1 Sanofi Pasteur Company Information

    • 11.3.2 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.3.3 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Sanofi Pasteur Main Business Overview

    • 11.3.5 Sanofi Pasteur Latest Developments

  • 11.4 GlaxoSmithKline

    • 11.4.1 GlaxoSmithKline Company Information

    • 11.4.2 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.4.3 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 GlaxoSmithKline Main Business Overview

    • 11.4.5 GlaxoSmithKline Latest Developments

  • 11.5 BioNTech

    • 11.5.1 BioNTech Company Information

    • 11.5.2 BioNTech Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.5.3 BioNTech Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 BioNTech Main Business Overview

    • 11.5.5 BioNTech Latest Developments

  • 11.6 Moderna

    • 11.6.1 Moderna Company Information

    • 11.6.2 Moderna Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.6.3 Moderna Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Moderna Main Business Overview

    • 11.6.5 Moderna Latest Developments

  • 11.7 Dynavax

    • 11.7.1 Dynavax Company Information

    • 11.7.2 Dynavax Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.7.3 Dynavax Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Dynavax Main Business Overview

    • 11.7.5 Dynavax Latest Developments

  • 11.8 Novavax

    • 11.8.1 Novavax Company Information

    • 11.8.2 Novavax Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.8.3 Novavax Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Novavax Main Business Overview

    • 11.8.5 Novavax Latest Developments

  • 11.9 Sino Biopharm

    • 11.9.1 Sino Biopharm Company Information

    • 11.9.2 Sino Biopharm Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.9.3 Sino Biopharm Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Sino Biopharm Main Business Overview

    • 11.9.5 Sino Biopharm Latest Developments

  • 11.10 Kangtai Bio

    • 11.10.1 Kangtai Bio Company Information

    • 11.10.2 Kangtai Bio Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.10.3 Kangtai Bio Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Kangtai Bio Main Business Overview

    • 11.10.5 Kangtai Bio Latest Developments

  • 11.11 Zhifei Biological

    • 11.11.1 Zhifei Biological Company Information

    • 11.11.2 Zhifei Biological Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.11.3 Zhifei Biological Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Zhifei Biological Main Business Overview

    • 11.11.5 Zhifei Biological Latest Developments

  • 11.12 Walvax

    • 11.12.1 Walvax Company Information

    • 11.12.2 Walvax Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.12.3 Walvax Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 Walvax Main Business Overview

    • 11.12.5 Walvax Latest Developments

  • 11.13 Minhai Biological

    • 11.13.1 Minhai Biological Company Information

    • 11.13.2 Minhai Biological Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.13.3 Minhai Biological Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 Minhai Biological Main Business Overview

    • 11.13.5 Minhai Biological Latest Developments

  • 11.14 Sinovac

    • 11.14.1 Sinovac Company Information

    • 11.14.2 Sinovac Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.14.3 Sinovac Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 Sinovac Main Business Overview

    • 11.14.5 Sinovac Latest Developments

  • 11.15 Wantai Biological

    • 11.15.1 Wantai Biological Company Information

    • 11.15.2 Wantai Biological Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.15.3 Wantai Biological Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 Wantai Biological Main Business Overview

    • 11.15.5 Wantai Biological Latest Developments

  • 11.16 Wanbangde Pharmaceutical

    • 11.16.1 Wanbangde Pharmaceutical Company Information

    • 11.16.2 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.16.3 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.16.4 Wanbangde Pharmaceutical Main Business Overview

    • 11.16.5 Wanbangde Pharmaceutical Latest Developments

  • 11.17 AIM Bio

    • 11.17.1 AIM Bio Company Information

    • 11.17.2 AIM Bio Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.17.3 AIM Bio Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.17.4 AIM Bio Main Business Overview

    • 11.17.5 AIM Bio Latest Developments

  • 11.18 Antejin Biotechnology

    • 11.18.1 Antejin Biotechnology Company Information

    • 11.18.2 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.18.3 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.18.4 Antejin Biotechnology Main Business Overview

    • 11.18.5 Antejin Biotechnology Latest Developments

  • 11.19 Lanzhou Institute of Biological Products

    • 11.19.1 Lanzhou Institute of Biological Products Company Information

    • 11.19.2 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.19.3 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.19.4 Lanzhou Institute of Biological Products Main Business Overview

    • 11.19.5 Lanzhou Institute of Biological Products Latest Developments

  • 11.20 Wuhan Institute of Biological Products

    • 11.20.1 Wuhan Institute of Biological Products Company Information

    • 11.20.2 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.20.3 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.20.4 Wuhan Institute of Biological Products Main Business Overview

    • 11.20.5 Wuhan Institute of Biological Products Latest Developments

  • 11.21 Beijing Institute of Biological Products

    • 11.21.1 Beijing Institute of Biological Products Company Information

    • 11.21.2 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.21.3 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.21.4 Beijing Institute of Biological Products Main Business Overview

    • 11.21.5 Beijing Institute of Biological Products Latest Developments

  • 11.22 Chengdu Institute of Biological Products

    • 11.22.1 Chengdu Institute of Biological Products Company Information

    • 11.22.2 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Offered

    • 11.22.3 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2021-2026)

    • 11.22.4 Chengdu Institute of Biological Products Main Business Overview

    • 11.22.5 Chengdu Institute of Biological Products Latest Developments

• 12 Research Findings and Conclusion